Last update 20 Mar 2025

SRK-181

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Niche modulators
Target
Action
inhibitors
Mechanism
TGF-β1 inhibitors(Transforming growth factor beta 1 inhibitors)
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Locally Advanced Malignant Solid NeoplasmPhase 1
South Korea
23 Apr 2020
Locally Advanced Malignant Solid NeoplasmPhase 1
United States
23 Apr 2020
Melanoma, Cutaneous MalignantPhase 1
South Korea
23 Apr 2020
Melanoma, Cutaneous MalignantPhase 1
United States
23 Apr 2020
Metastatic Solid TumorPhase 1
South Korea
23 Apr 2020
Metastatic Solid TumorPhase 1
United States
23 Apr 2020
Non-Small Cell Lung CancerPhase 1
South Korea
23 Apr 2020
Non-Small Cell Lung CancerPhase 1
United States
23 Apr 2020
Squamous Cell Carcinoma of Head and NeckPhase 1
United States
23 Apr 2020
Squamous Cell Carcinoma of Head and NeckPhase 1
South Korea
23 Apr 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
Advanced Malignant Solid Neoplasm
Second line
immunohistochemistry | flow cytometry
72
SRK-181 (linavonkibart) 1500mg q3w + pembrolizumab
(tpteehpbdi) = The most common (TRAE, ≥10%) of any grade were rash (23.6%), pruritus (20.8%), fatigue (19.4%) and diarrhea (12.5%). qlpnocymvz (fmprcmineo )
Positive
24 May 2024
SRK-181 + pembrolizumab
(HNSCC)
Phase 1
-
suntkvaqzf(vldcnzmobz) = 11%, n=2 vtjlyadocl (fsrioylsbg )
Positive
07 Nov 2022
SRK-181 2000mg q2w
Phase 1
29
(monotherapy)
(hueehjbqdb) = rhdxwlddad mgbirfoxlz (dsiirvquvq )
Positive
12 Nov 2021
(combination therapy)
(hueehjbqdb) = biqbflonme mgbirfoxlz (dsiirvquvq )
Phase 1
25
tyduuhkqjl(krnyaeotlz) = One RECIST1.1 PR (800mg) was observed in a patient with anti-PD-1 resistant RCC dyefkpdrgq (zzfrllnvuf )
Positive
10 Nov 2021
SRK-181 + pembrolizumab
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free